 People with HIV taking the dolutegravir (DTG) drug could be at an increased risk of developing high blood pressure, according to a study. The World Health Organisation (WHO), in 2019, formally recommended the drug dolutegravir (DTG) as the preferred antiretroviral therapy (ART) for people living with HIV in low and middle-income countries (LMICs),